Princeton-based Certara, a global model-informed drug development and decision support leader, announced on Tuesday the launch of BaseCase Data Studio, the newest product for its BaseCase value communications platform.
Certara’s BaseCase platform enables pharmaceutical and MedTech clients to build interactive, data-driven mobile apps using real-world data sources, such as health care claims, costs, quality, outcomes, and population data to demonstrate the value of specific drugs or devices during cost discussions with payers, providers and health care professionals (HCPs).
According to Certara, with the addition of BaseCase Data Studio, clients can now also perform sophisticated statistical modeling and data analyses live on their mobile apps during those meetings.
“Due to rising health care costs, payers, providers and health care professionals are increasingly turning to evidence-based medicine and are seeking to gain meaningful insights from the huge volumes of available health care data to enable them to make the best value-based decisions regarding new drugs and devices,” said Thomas Kerbusch, president of Certara Strategic Consulting. “Using BaseCase Data Studio, our clients can now conduct the requisite analyses in real-time and accurately predict a range of outcomes, thus supporting their value messages with evidence-based claims,” Kerbusch said.
The programming language R is widely used by modelers, statisticians and data scientists in the life science industry. Much of the pharmacometrics, health economics and outcomes research, and epidemiology modeling, which is central to Certara’s staff and customers’ work, is performed in R. Data Studio unlocks the power of those advanced models in value communication. The commonly used R packages Heemod and deSolve are supported by BaseCase Data Studio “out-of-the-box.”
Using BaseCase Data Studio, Certara’s clients can create mobile tools that generate simulations (including Markov chains and discrete event simulation) and budget impact models; conduct meta-analyses; perform multi-criteria decision, cost-effectiveness, health-related quality of life and probabilistic sensitivity analyses.